While ARG098 is a new potentially effective tool for the inhibition of synovial hyperplasia and joint swelling, ARG098 could also possibly affect normal cells that express Fas on the cell surface and this may lead to adverse events during RA treatment. This evidence concerns the gene FAS and rheumatoid arthritis.